全文获取类型
收费全文 | 1983篇 |
免费 | 150篇 |
国内免费 | 30篇 |
专业分类
耳鼻咽喉 | 38篇 |
儿科学 | 34篇 |
妇产科学 | 37篇 |
基础医学 | 206篇 |
口腔科学 | 11篇 |
临床医学 | 233篇 |
内科学 | 446篇 |
皮肤病学 | 33篇 |
神经病学 | 168篇 |
特种医学 | 116篇 |
外科学 | 298篇 |
综合类 | 113篇 |
预防医学 | 153篇 |
眼科学 | 72篇 |
药学 | 114篇 |
肿瘤学 | 91篇 |
出版年
2023年 | 15篇 |
2021年 | 33篇 |
2020年 | 17篇 |
2019年 | 25篇 |
2018年 | 28篇 |
2017年 | 17篇 |
2016年 | 35篇 |
2015年 | 24篇 |
2014年 | 40篇 |
2013年 | 57篇 |
2012年 | 69篇 |
2011年 | 92篇 |
2010年 | 52篇 |
2009年 | 47篇 |
2008年 | 62篇 |
2007年 | 92篇 |
2006年 | 60篇 |
2005年 | 60篇 |
2004年 | 63篇 |
2003年 | 58篇 |
2002年 | 64篇 |
2001年 | 60篇 |
2000年 | 70篇 |
1999年 | 39篇 |
1998年 | 40篇 |
1997年 | 26篇 |
1996年 | 20篇 |
1995年 | 29篇 |
1994年 | 28篇 |
1993年 | 28篇 |
1992年 | 55篇 |
1991年 | 53篇 |
1990年 | 62篇 |
1989年 | 60篇 |
1988年 | 78篇 |
1987年 | 40篇 |
1986年 | 45篇 |
1985年 | 57篇 |
1984年 | 50篇 |
1983年 | 34篇 |
1982年 | 28篇 |
1981年 | 27篇 |
1980年 | 22篇 |
1979年 | 23篇 |
1978年 | 25篇 |
1977年 | 28篇 |
1976年 | 23篇 |
1975年 | 16篇 |
1974年 | 16篇 |
1973年 | 18篇 |
排序方式: 共有2163条查询结果,搜索用时 31 毫秒
61.
Marijt WA; Veenhof WF; Goulmy E; Willemze R; van Rood JJ; Falkenburg JH 《Blood》1993,82(12):3778-3785
HLA-identical bone marrow transplantation (BMT) may be complicated by graft-versus-host disease or graft rejection. Both complications are thought to be initiated by recognition of minor histocompatibility (mH) antigens by HLA-restricted mH-antigen-specific T lymphocytes. Using HLA- A2-restricted mH antigens HA-1-, -2-, and -4-, and HY-specific cytotoxic T lymphocyte (CTL) clones, we studied the recognition by these CTL clones of interleukin-2 (IL-2)-stimulated T cells (IL-2 blasts), BM mononuclear cells (BMMNCs), and hematopoietic progenitor cells (HPCs). We showed that, when IL-2 blasts from the BM donors who were investigated were recognized by the HA-1-, -2-, and -4-, and HY- specific CTL clones, their BMMNCs and HPCs were recognized as well by these CTL clones, resulting in antigen-specific growth inhibition of erythrocyte burst-forming units (BFU-E), colony-forming units- granulocyte (CFU-G), and CFU-macrophage (CFU-M). the HA-2-specific CTL clone, however, inhibited BFU-E and CFU-G growth from four donors to a lesser extent than from two other donors. We further investigated whether inhibitory cytokines released into the culture medium by the antigen-specific stimulated CTLs or by stimulated BMMNCs were responsible for suppression of HPC growth or whether this effect was caused by direct cell-cell contact between CTLs and HPCs. HPC growth inhibition was only observed after preincubation of BMMNCs and CTLs together for 4 hours before plating the cells in semisolid HPC culture medium. When no cell-cell contact was permitted before plating, neither antigen-stimulated CTL nor antigen-nonstimulated CTLs provoked HPC growth inhibition. Culturing BMMNCs in the presence of supernatants harvested after incubation of BMMNCs and CTL clones together for 4 or 72 hours did also not result in HPC growth inhibition. Both suppression of HPC growth and lysis of IL-2 blasts and BMMNCs in the 51Cr-release assay appeared to be dependent on direct cell-cell contact between target cells and CTLs and were not caused by the release of inhibitory cytokines into the culture medium by antigen-specific stimulated CTLs or by stimulated BMMNCs. Our results show that mH-antigen-specific CTLs can inhibit HPC growth by a direct cytolytic effect and may therefore be responsible for BM graft rejection after HLA-identical BMT. 相似文献
62.
OBJECTIVES: To define the level of pathogen-specific immune reconstitution persisting over 3 to 5 years of highly active antiretroviral therapy (HAART) in HIV-infected patients who began therapy with CD4 T-cell counts below 50 cells/microL. METHODS: Cytomegalovirus (CMV)-specific T-cell responses were analysed in adult HIV-1-infected patients with nadir CD4 T-cell counts below 50 cells/microL before HAART. CMV-specific CD4 T-cell responses were measured by interferon-gamma enzyme-linked immunospot assay (ELISpot assay), lymphoproliferation and interferon-gamma levels in cell culture supernatants. RESULTS: CD4 T-cell responses to CMV were low in untreated patients and remained low during the first year on HAART, but increased progressively to levels similar to those found in HIV-seronegative CMV-seropositive controls at 3 years. Responses then declined markedly and at 5 years were lower than controls. This could not be explained by changes in CD4 or CD8 T-cell counts or plasma HIV RNA levels. Interferon-gamma and interleukin-5 responses to a mitogen were maintained or elevated. CONCLUSIONS: CMV-specific CD4 T-cell responses were found to decline after 3-5 years on HAART and may provide inadequate long-term protection against CMV disease in patients who are severely immunodeficient prior to treatment. 相似文献
63.
64.
Jones K Nourse JP Keane C Crooks P Gottlieb D Ritchie DS Gill D Gandhi MK 《American journal of hematology》2012,87(3):258-265
Recently, nontumor specific circulating DNA was shown to be elevated in a broad range of lymphomas, implicating a role as a potential biomarker. Epstein-Barr virus' (EBV) presence within a proportion of lymphomas implies EBV-DNA has potential as a lymphoma-specific disease response biomarker. However, application would be restricted to EBV-associated lymphomas. Neither detailed comparison has been performed of lymphoma-specific versus nonspecific DNA as disease response biomarkers nor have the kinetics of circulating DNA during treatment been established, and the optimal methodology remains unknown. We prospectively evaluated DNA levels and clinical response of 63 lymphoma patients. DNA was measured in paired serum, plasma, and cell samples at five predetermined time-points taken prior, during and following treatment. Both cell-free (c-f) circulating EBV-DNA (in EBV-associated lymphoma) and nonspecific c-f DNA levels (in all lymphomas) were elevated and discriminatory at presentation compared to healthy controls. Nonspecific c-f DNA was significantly associated with baseline serum lactate dehydrogenase. Within EBV-associated lymphomas at presentation, there was a strong correlation between specific and nonspecific circulating c-f DNA (r = 0.9, P < 0.0001). However, only c-f EBV-DNA correlated with clinical/radiological response. In addition, c-f EBV-DNA, and not nonspecific c-f DNA, provided an early marker of relapsed and refractory disease. Serum versus plasma, and single versus multiple-copy EBV-gene targets were equivalent. Lymphoma-specific DNA is a disease response biomarker; however, nonspecific DNA reflected neither lymphoma-specific DNA nor therapeutic response. Lymphoma disease response can be monitored by blood tests, but new lymphoma-specific biomarkers need to be identified to broaden applicability. 相似文献
65.
Calkins H Kuck KH Cappato R Brugada J Camm AJ Chen SA Crijns HJ Damiano RJ Davies DW DiMarco J Edgerton J Ellenbogen K Ezekowitz MD Haines DE Haissaguerre M Hindricks G Iesaka Y Jackman W Jalife J Jais P Kalman J Keane D Kim YH Kirchhof P Klein G Kottkamp H Kumagai K Lindsay BD Mansour M Marchlinski FE McCarthy PM Mont JL Morady F Nademanee K Nakagawa H Natale A Nattel S Packer DL Pappone C Prystowsky E Raviele A Reddy V Ruskin JN Shemin RJ Tsao HM Wilber D 《Europace : European pacing, arrhythmias, and cardiac electrophysiology》2012,14(4):528-606
66.
Andrew D. Hardie William J. Rieter Marques L. Bradshaw Leonie L. Gordon Matthew A. Young Thomas E. Keane 《World journal of urology》2013,31(6):1327-1332
Purpose
To preliminarily evaluate the potential for an improvement in diagnostic performance by a combined interpretation of In-111 capromab pendetide single photon emission computed tomography (SPECT) including computed tomography (CT) image fusion with magnetic resonance diffusion-weighted imaging (MR-DWI) for identifying prostate cancer in pelvic lymph nodes thru correlation with histopathology.Materials and methods
This institutional approved, retrospective study identified patients with available histopathology of lymph nodes removed at the time of radical prostatectomy and who had undergone staging with In-111 capromab pendetide SPECT-CT and/or pelvic MRI (including DWI). The performance of In-111 capromab pendetide SPECT for identifying malignant lymph nodes was assessed. Subsequently, a combined reading of In-111 capromab pendetide SPECT and prostate MRI with DWI was performed and the performance assessed.Results
18 patients underwent In-111 capromab pendetide SPECT-CT. Of these, 12 patients had also undergone imaging with MR-DWI. In-111 capromab pendetide SPECT-CT had a sensitivity of 40.0 % and specificity of 96.7 % for identification of malignant lymph nodes. However, In-111 capromab pendetide SPECT-CT combined with MRI with DWI had a sensitivity of 88.9 % and specificity of 98.5 %.Conclusions
The addition of MR-DWI to the interpretation of In-111 capromab pendetide SPECT-CT may increase the sensitivity for detecting malignant lymph nodes in prostate cancer. Future prospective evaluation of combined In-111 capromab pendetide SPECT-CT and MR-DWI is indicated and may improve clinical evaluation of nodal disease in prostate cancer. 相似文献67.
Katherine N Bachmann Alexander G Bruno Miriam A Bredella Melanie Schorr Elizabeth A Lawson Corey M Gill Vibha Singhal Erinne Meenaghan Anu V Gerweck Kamryn T Eddy Seda Ebrahimi Stuart L Koman James M Greenblatt Robert J Keane Thomas Weigel Esther Dechant Madhusmita Misra Anne Klibanski Karen K Miller 《Journal of bone and mineral research》2016,31(2):281-288
Somewhat paradoxically, fracture risk, which depends on applied loads and bone strength, is elevated in both anorexia nervosa and obesity at certain skeletal sites. Factor‐of‐risk (Φ), the ratio of applied load to bone strength, is a biomechanically based method to estimate fracture risk; theoretically, higher Φ reflects increased fracture risk. We estimated vertebral strength (linear combination of integral volumetric bone mineral density [Int.vBMD] and cross‐sectional area from quantitative computed tomography [QCT]), vertebral compressive loads, and Φ at L4 in 176 women (65 anorexia nervosa, 45 lean controls, and 66 obese). Using biomechanical models, applied loads were estimated for: 1) standing; 2) arms flexed 90°, holding 5 kg in each hand (holding); 3) 45° trunk flexion, 5 kg in each hand (lifting); 4) 20° trunk right lateral bend, 10 kg in right hand (bending). We also investigated associations of Int.vBMD and vertebral strength with lean mass (from dual‐energy X‐ray absorptiometry [DXA]) and visceral adipose tissue (VAT, from QCT). Women with anorexia nervosa had lower, whereas obese women had similar, Int.vBMD and estimated vertebral strength compared with controls. Vertebral loads were highest in obesity and lowest in anorexia nervosa for standing, holding, and lifting (p < 0.0001) but were highest in anorexia nervosa for bending (p < 0.02). Obese women had highest Φ for standing and lifting, whereas women with anorexia nervosa had highest Φ for bending (p < 0.0001). Obese and anorexia nervosa subjects had higher Φ for holding than controls (p < 0.03). Int.vBMD and estimated vertebral strength were associated positively with lean mass (R = 0.28 to 0.45, p ≤ 0.0001) in all groups combined and negatively with VAT (R = –[0.36 to 0.38], p < 0.003) within the obese group. Therefore, women with anorexia nervosa had higher estimated vertebral fracture risk (Φ) for holding and bending because of inferior vertebral strength. Despite similar vertebral strength as controls, obese women had higher vertebral fracture risk for standing, holding, and lifting because of higher applied loads from higher body weight. Examining the load‐to‐strength ratio helps explain increased fracture risk in both low‐weight and obese women. © 2015 American Society for Bone and Mineral Research. 相似文献
68.
Emma Gannan MBBS Jeremy Khoo MBBS Sophie Nightingale MBBS FRACS Thomas Surya Suhardja MBBS Jocelyn Lippey MBBS FRACS Holly Keane MBBS FRACS Kian Jin Tan MBBS David Clouston MBBS FRACPA Alexandra Gorelik PhD Gregory Bruce Mann MBBS PhD FRACS The Melbourne Breast Group 《The breast journal》2016,22(4):413-419
To examine practice patterns for breast cancer patients with limited sentinel node (SN) disease in light of the ACOSOG Z0011 results. Retrospective analysis of patients with T1‐2 breast cancer and positive sentinel lymph node biopsy (SLNB) admitted between January 2009 and December 2012. Patient demographics, tumor characteristics, and treatments were recorded. Eight hundred positive SLNBs were identified. A total of 452 (56.5%) proceeded to completion axillary lymph node dissection (cALND). cALND rate decreased from 65.1% to 49.7% from 2009–2010 to 2011–2012. cALND was performed for micrometastasis or isolated tumor cells in 39.3% in 2009–2010 and 22.2% in 2011–2012, whereas for macrometastases the rates were 83.1% and 68.6%, respectively. cALND rates diminished for both Z0011‐eligible and ‐ineligible patients. The ACOSOG Z0011 trial presentation and publication coincided with a reduction in cALND for breast cancer with limited nodal disease. There appears equipoise regarding management of macrometastatic SN disease. 相似文献
69.
Population‐based validation of the recursive partitioning analysis–based staging system for oropharyngeal cancer 下载免费PDF全文
70.